PL375043A1 - Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin, useful for the treatment of cancer and infectious disease - Google Patents

Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin, useful for the treatment of cancer and infectious disease

Info

Publication number
PL375043A1
PL375043A1 PL02375043A PL37504302A PL375043A1 PL 375043 A1 PL375043 A1 PL 375043A1 PL 02375043 A PL02375043 A PL 02375043A PL 37504302 A PL37504302 A PL 37504302A PL 375043 A1 PL375043 A1 PL 375043A1
Authority
PL
Poland
Prior art keywords
macroglobulin
cancer
alpha
useful
treatment
Prior art date
Application number
PL02375043A
Other languages
English (en)
Polish (pl)
Inventor
Pramod K. Srivastava
Original Assignee
University Of Connecticut Health Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Connecticut Health Center filed Critical University Of Connecticut Health Center
Publication of PL375043A1 publication Critical patent/PL375043A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL02375043A 2001-08-20 2002-08-20 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin, useful for the treatment of cancer and infectious disease PL375043A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31362901P 2001-08-20 2001-08-20
US33722201P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
PL375043A1 true PL375043A1 (en) 2005-11-14

Family

ID=26978972

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02375043A PL375043A1 (en) 2001-08-20 2002-08-20 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin, useful for the treatment of cancer and infectious disease

Country Status (12)

Country Link
US (1) US7666581B2 (https=)
EP (1) EP1536829A4 (https=)
JP (1) JP4384489B2 (https=)
KR (1) KR20040064688A (https=)
CN (1) CN1635896A (https=)
AU (1) AU2002335654B2 (https=)
CA (1) CA2457008A1 (https=)
HK (1) HK1079705A1 (https=)
IL (1) IL160511A0 (https=)
PL (1) PL375043A1 (https=)
RU (2) RU2335295C2 (https=)
WO (1) WO2003015712A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
RU2324493C2 (ru) * 2003-02-20 2008-05-20 Юниверсити Оф Коннектикут Хелт Сентер Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
WO2005120558A2 (en) * 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
US8754094B2 (en) * 2007-08-15 2014-06-17 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
AU2013222414B2 (en) 2012-02-21 2018-02-15 Cytonics Corporation Systems, compositions, and methods for transplantation
CN103372209B (zh) * 2012-04-24 2014-09-17 中国科学院微生物研究所 gp96蛋白的抗体在制备癌细胞抑制剂中的应用
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
BR112017016681A2 (pt) * 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
RU2640017C1 (ru) * 2016-10-31 2017-12-25 Алла Анатольевна Ляшенко Способ получения биологического материала для создания аутологичных противоопухолевых вакцин
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
CN115896044B (zh) * 2022-11-07 2026-03-06 江苏省农业科学院 一种高效的猪流行性腹泻病毒纯化方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US192230A (en) * 1877-06-19 Improvement in ironing-tables
US172682A (en) * 1876-01-25 Improvement in tool-carrier attachments to screw-machines
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US28207A (en) * 1860-05-08 Alfred b
US211971A (en) * 1879-02-04 Improvement in centrifugal drying-machines
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1989012455A1 (en) 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1990002564A1 (en) 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) 1990-07-25 1990-09-12 Burnie James P Medicaments
CA2095855C (en) 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2688227A1 (fr) 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2130089A1 (en) 1992-03-09 1993-09-16 Aldo Mancini Protein compound, coding nucleotide sequences, producing cell line and uses thereof
EP0636248A4 (en) 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
AU5873994A (en) 1992-12-18 1994-07-19 Duke University Immune response modulator complex, and uses thereof
US5496934A (en) * 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
WO1997006821A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997010000A1 (en) * 1995-09-13 1997-03-20 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
CA2251781A1 (en) * 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
IN183280B (https=) 1996-09-20 1999-10-30 Univ New Mexico
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US5947646A (en) 1997-02-25 1999-09-07 Guardian Fiberglass, Inc. System for blowing loose-fill insulation
BE1011033A6 (fr) 1997-03-05 1999-04-06 Univ Bruxelles Composition pharmaceutique et/ou alimentaire pour le traitement de pathologies liees a un rejet de greffe, une reaction allergique ou auto-immune ou du cancer.
US6709672B2 (en) 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
WO1998046743A1 (en) 1997-04-15 1998-10-22 The Wellcome Trust Limited As Trustee To The Wellcome Trust Novel ldl-receptor
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6403092B1 (en) 1998-04-01 2002-06-11 Duke University Immune response modulator alpha-2 macroglobulin complex
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6730302B1 (en) 1998-11-24 2004-05-04 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kD heat shock protein
JP2002539174A (ja) 1999-03-17 2002-11-19 エントレメッド インコーポレイテッド 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
US7179462B2 (en) * 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
WO2002011669A2 (en) * 2000-08-07 2002-02-14 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
AU2001286775A1 (en) 2000-08-25 2002-03-04 Duke University Adjuvant
AU2001294560B2 (en) 2000-09-15 2007-06-21 University Of Connecticut Health Center Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
CA2422867A1 (en) 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US7132109B1 (en) * 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US20020172682A1 (en) 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US20030211971A1 (en) 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003092624A2 (en) 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
RU2324493C2 (ru) 2003-02-20 2008-05-20 Юниверсити Оф Коннектикут Хелт Сентер Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней

Also Published As

Publication number Publication date
JP4384489B2 (ja) 2009-12-16
HK1079705A1 (zh) 2006-04-13
CA2457008A1 (en) 2003-02-27
RU2004108129A (ru) 2005-04-20
JP2005511495A (ja) 2005-04-28
EP1536829A4 (en) 2006-05-31
AU2002335654B2 (en) 2008-02-21
WO2003015712A2 (en) 2003-02-27
IL160511A0 (en) 2004-07-25
RU2335295C2 (ru) 2008-10-10
CN1635896A (zh) 2005-07-06
WO2003015712A3 (en) 2005-04-14
RU2008120299A (ru) 2009-11-27
KR20040064688A (ko) 2004-07-19
US7666581B2 (en) 2010-02-23
US20030129196A1 (en) 2003-07-10
EP1536829A2 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
PL375043A1 (en) Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin, useful for the treatment of cancer and infectious disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
EP1453536A4 (en) COMPOSITION FOR PRESERVING VIRUSES
IL161070A0 (en) Compositions for the treatment of infectious diseases
GB0100758D0 (en) Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL161352A0 (en) Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
HUP0402259A3 (en) Vaccines
AU2002312303A1 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
SG113427A1 (en) Heat treatment of titanium-alloy article having martensitic structure
IL157251A0 (en) Hepatitis b virus treatment
PL368935A1 (en) Methods of treating pulmonary disease
DE60212762D1 (de) Vakuumbehandlungsofen
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
IL156647A0 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
HK1077757A (en) Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
GB0105238D0 (en) Vaccines
GB0128628D0 (en) Disease treatment
AU2002342188A8 (en) Methods and compositions for treating flavivirus-mediated disease
AU2002353915A1 (en) Methods and compositions for treating rotavirus-mediated disease
AU2002309857A1 (en) Vaccines for the treatment of autoimmune disease

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)